leadf
logo-loader
viewEmyria Ltd

Emerald Clinics set to benefit from interim TGA decision to down schedule CBD

The company’s strategy of generating high-quality clinical evidence on the safety and efficacy of new treatments, including CBD, makes it well-positioned to benefit from the changes announced by the TGA.

Emerald Clinics Ltd - Emerald Clinics set to benefit from interim TGA decision to down schedule CBD
The TGA will undertake a second consultation period with a closing deadline of October 13

Emerald Clinics Ltd (ASX:EMD) welcomes the interim decision from Australia’s Therapeutic Goods Administration (TGA) that recommends low dose cannabidiol, or CBD, become a Schedule 3 medicine on the Australian Register of Therapeutic Goods (ARTG).

The interim ruling outlined the process for low dose CBD to be registered as a Schedule 3 medicine at the 60mg/day limit.

Registration of low dose CBD would require a full submission to the TGA and high-quality clinical evidence to support safety and effectiveness.

The TGA interim decision could allow patients to purchase low dose CBD as a pharmacist only or over-the-counter medication for specific indications.

Advertising to consumers would not be permitted and higher doses of CBD and other cannabinoid medicines would still require a prescription from a medical practitioner.

“Encouraged by meaningful commitment”

Emerald Clinics' chief executive officer Dr Michael Winlo said: “Regulators play an important role ensuring medicines are safe and effective before they are available to patients which is why they require independent and high-quality clinical evidence to support their recommendations.

“Emerald exists to generate product-specific real-world evidence packages and insights that can support regulators, like the TGA and others involved in these decisions around the globe, together with developers of CBD and other new treatments.

“We are encouraged by this meaningful commitment to bring evidence-based, innovative therapies to patients.”

The TGA will undertake a second consultation period with a closing deadline of October 13 and expects to make a final decision on February 1.

Quick facts: Emyria Ltd

Price: 0.078 AUD

ASX:EMD
Market: ASX
Market Cap: $16.49 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Emyria Ltd named herein, including the promotion by the Company of Emyria Ltd in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Emyria's Michael Winlo details new global partnership with UK-based Sapphire...

Emyria Ltd’s (ASX:EMD) Dr Michael Winlo caught up with Proactive's Andrew Scott after reporting that its clinical operations subsidiary, Emerald Clinics, has entered into a global partnership with UK-based Sapphire Medical Clinics. The partnership will provide a new source of data to bolster...

1 week, 1 day ago

2 min read